TAC1 and depressive disorder: Acting through NK1 receptors, substance P contributes to mood and anxiety disorders, making NK1 receptor antagonists a promising therapeutic strategy for depression, anxiety, and PTSD, as suggested by findings from a limited number of clinical trials [148].